Literature DB >> 9168830

Quinolinate immunoreactivity in experimental rat brain tumors is present in macrophages but not in astrocytes.

J R Moffett1, T Els, M G Espey, S A Walter, W J Streit, M A Namboodiri.   

Abstract

Experimental tumors of the central nervous system were investigated with antibodies to quinolinate to assess the cellular distribution of this endogenous neurotoxin. In advanced F98 and RG-2 glioblastomas and E367 neuroblastomas in the striatum of rats, variable numbers of quinolinate immunoreactive cells were observed in and around the tumors, with the majority being present within tumors, rather than brain parenchyma. The stained cells were morphologically variable, including round, complex, rod-shaped, and sparsely dendritic cells. Neuroblastoma and glioma cells were unstained, as were neurons, astrocytes, oligodendrocytes, ependymal cells, endothelial cells, and cells of the choroid plexus and leptomeninges. Glial fibrillary acidic protein immunoreactivity was strongly elevated in astrocytes surrounding the tumors. Dual labeling immunohistochemistry with antibodies to quinolinate and glial fibrillary acidic protein demonstrated that astrocytes and the cells containing quinolinate immunoreactivity were morphologically disparate and preferentially distributed external and internal to the tumors, respectively, and no dual labeled cells were observed. Lectin histochemistry with Griffonia simplicifolia B4 isolectin and Lycopersicon esculentum lectin demonstrated numerous phagocytic macrophages and reactive microglia in and around the tumors whose distribution was similar to that of quinolinate immunoreactive cells, albeit much more numerous. Dual labeling studies with antibodies to quinolinate and the lectins demonstrated partial codistribution of these markers, with most double-labeled cells having the morphology of phagocytes. The present findings suggest the possibility that quinolinate may serve a functional role in a select population of inflammatory cell infiltrates during the immune response to brain neoplasms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168830     DOI: 10.1006/exnr.1996.6365

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  14 in total

1.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

Review 2.  Involvement of quinolinic acid in AIDS dementia complex.

Authors:  Gilles J Guillemin; Stephen J Kerr; Bruce J Brew
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

3.  Crystal structure of Homo sapiens kynureninase.

Authors:  Santiago Lima; Roman Khristoforov; Cory Momany; Robert S Phillips
Journal:  Biochemistry       Date:  2007-02-15       Impact factor: 3.162

4.  Magnetic labeling of activated microglia in experimental gliomas.

Authors:  G Fleige; C Nolte; M Synowitz; F Seeberger; H Kettenmann; C Zimmer
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

Review 5.  Tryptophan, adenosine, neurodegeneration and neuroprotection.

Authors:  T W Stone; C M Forrest; G M Mackay; N Stoy; L G Darlington
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

6.  The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation.

Authors:  Wei Chen; Xueqing Liang; Amanda J Peterson; David H Munn; Bruce R Blazar
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

7.  Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma.

Authors:  Noelyn A Hung; Ramona A Eiholzer; Stenar Kirs; Jean Zhou; Kirsten Ward-Hartstonge; Anna K Wiles; Chris M Frampton; Ahmad Taha; Janice A Royds; Tania L Slatter
Journal:  Mod Pathol       Date:  2016-01-15       Impact factor: 7.842

8.  The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.

Authors:  Anna Zinger; Carlos Barcia; Maria Trinidad Herrero; Gilles J Guillemin
Journal:  Parkinsons Dis       Date:  2011-06-03

Review 9.  Modulation of tumor tolerance in primary central nervous system malignancies.

Authors:  Theodore S Johnson; David H Munn; Bernard L Maria
Journal:  Clin Dev Immunol       Date:  2012-01-24

10.  Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease.

Authors:  Simon P Jones; Nunzio F Franco; Bianca Varney; Gayathri Sundaram; David A Brown; Josien de Bie; Chai K Lim; Gilles J Guillemin; Bruce J Brew
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.